Hear the experts discuss the benefits of the RNS System
Conclusive Evidence.
Long-Term Seizure
Reduction
82% median seizure reduction at 3 years1
Rapid Seizure
Reduction
62% median seizure reduction at 6 months1
Results from the RNS System Post-Approval Study, the largest FDA-reviewed prospective neuromodulation study in focal drug-resistant epilepsy, confirm rapid and sustained seizure control, with outcomes from 324 implanted patients at 32 centers across the U.S.1,6,7
Seizure Freedom is Possible
42% of patients seizure free for 6+ months1,9
(n=268)
Seizure Freedom at Last Follow-up
Proven Choice for Patients
Lower rate of SUDEP vs ASM Placebo10
Effectively treats a variety of focal onset zones
1 in 3 patients did not require intracranial monitoring1
Stay at the forefront of epilepsy treatment.
Sign up for the NeuroPace newsletter to receive updates on the latest research and innovations.
Note: Therapies were studied using different study designs. Caution must be exercised when comparing results.
- RNS System Post-approval Study Oral Presentation, American Academy of Neurology, April 2025, all outcomes are ITT, median seizure reduction is observed case data, seizure freedom at last follow-up is LOCF
- Morris et al, Neurology, 1999
- Kaufmann et al., Epilepsia, 2024
- VNS Prospective Trial (E01, E04 Pooled): https://www.accessdata.fda.gov/cdrh_docs/pdf/p970003.pdf
- Peltola et al., Neurology, 2023
- Salanova et al., 2015
- DeGiorgio et al, Epilepsia, 2000
- Englot et al, Neurosurgery, 2016
- At some point during the study
- Compared to placebo arm of ASM trial. 2.3/1000 patient years rate of SUDEP vs 6.9/1000 patient years rate of SUDEP in Anti-seizure Medication (ASM) placebo; Ryvlin et al, Lancet Neurol, 2011
Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important safety information at https://www.neuropace.com/safety/. Refer to the labeling for a description of the RNS® System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use. ©2025 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA 94043. NP 200156 Rev 2 / Rev. Date: 2025-03
